{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:31:16Z","timestamp":1791268276365,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Department of Orthopedics"},{"DOI":"10.13039\/100019688","name":"Department of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019688","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MGH Care Redesign Initiative program"},{"name":"Clinical Impact Research Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inpatient zoledronic acid (IP-ZA) administered during the initial fracture hospitalization significantly improves the osteoporosis treatment rate. Clinical outcomes of IP-ZA after hip fracture remain uncertain. Here we report a cohort study that emulated a randomized controlled trial using real-world data and evaluated the risk of all-cause-mortality and radiologically confirmed subsequent new fractures among patients hospitalized for a hip fracture who had received IP-ZA as compared with propensity-matched controls. A total of 654 patients who had received IP-ZA and 6877 controls (for whom anti-osteoporosis treatment was indicated but no IP-ZA started during index hospitalization) were included in the study. The primary cohort comprised 652 IP-ZA patients (IP-ZA group) and 1926 matched controls (untreated group), with 71.7% female 92.1% White participants, with a mean age of 80.9\u00a0years. Cumulative all-cause mortality over the 24-month follow-up for the IP-ZA group was 12.3% and 20.7% for the untreated group (hazard ratio [HR], 0.62; 95% CI, 0.49-0.78, p\u2009&amp;lt;\u2009.001). A total of 585 (89.7%) patients in IP-ZA group received only a single dose of ZA during the 24\u00a0months, and the death rate of this single dose group was 13.3%, which was significantly lower than that of the untreated group (HR, 0.70; 95% CI, 0.55-0.89, p\u00a0=\u00a0.003). Rates of radiologically confirmed cumulative subsequent new vertebral fractures were 2.0% in the IP-ZA group and 5.4% in the untreated group (HR, 0.40; 95% CI, 0.22-0.71, p\u00a0=\u00a0.001). A similarly lower rate of new vertebral fractures was seen in the single dose subgroup (1.9% vs 5.4%; HR, 0.44; 95% 0.24-0.82, p\u00a0=\u00a0.008). IP-ZA, administered during the initial hospitalization for hip fracture, was associated with lower all-cause-mortality and risk of radiologically confirmed subsequent new vertebral fractures, and thus offers a mechanism to narrow the treatment gap in patients having sustained a hip fragility fracture.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae101","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T16:13:41Z","timestamp":1719591221000},"source":"Crossref","is-referenced-by-count":12,"title":["Zoledronic acid for hip fracture during initial hospitalization"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-4809","authenticated-orcid":false,"given":"WuQiang","family":"Fan","sequence":"first","affiliation":[{"name":"Endocrine Division, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Sun","sequence":"additional","affiliation":[{"name":"Endocrine Division, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Endocrine Division, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuan V","family":"Ly","sequence":"additional","affiliation":[{"name":"Harvard Orthopaedic Trauma Initiative, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles T","family":"Pu","sequence":"additional","affiliation":[{"name":"Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Franco-Garcia","sequence":"additional","affiliation":[{"name":"Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy B","family":"Bolster","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Massachusetts General Hospital , Boston, MA 02114, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"9","key":"2024080208112565000_ref1","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1210\/jc.2017-02656","article-title":"Persistence of excess mortality following individual nonhip fractures: a relative survival analysis","volume":"103","author":"Tran","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024080208112565000_ref2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jbmr.4821","article-title":"Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality","volume":"38","author":"Sing","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"18","key":"2024080208112565000_ref3","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"2024080208112565000_ref4","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.2301","article-title":"The osteoporosis treatment gap","volume":"29","author":"Kanis","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024080208112565000_ref5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1210\/clinem\/dgac508","article-title":"Inpatient zoledronic acid and integrated orthopedic and fracture liaison services improve osteoporosis treatment rates","volume":"108","author":"Fan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024080208112565000_ref6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(22)00322-9","article-title":"Osteoporosis in the USA: prevention and unmet needs","volume":"11","author":"Khosla","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024080208112565000_ref7","article-title":"Additional insights on the osteoporosis care gap","volume":"38","author":"Talevski","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024080208112565000_ref8","doi-asserted-by":"crossref","first-page":"e1282","DOI":"10.1210\/clinem\/dgad295","article-title":"Safety of inpatient zoledronic acid in the immediate post-fracture setting","volume":"108","author":"Fan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024080208112565000_ref9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/endrev\/bnab007","article-title":"Conducting real-world evidence studies on the clinical outcomes of diabetes treatments","volume":"42","author":"Schneeweiss","year":"2021","journal-title":"Endocr Rev"},{"issue":"18","key":"2024080208112565000_ref10","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMp2200089","article-title":"Real-world evidence\u2014where are we now?","volume":"386","author":"Concato","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2024080208112565000_ref11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2024080208112565000_ref12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans","volume":"386","author":"Dickerman","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2024080208112565000_ref13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36023","article-title":"Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review","volume":"6","author":"Hansford","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2024080208112565000_ref14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"3","key":"2024080208112565000_ref15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"issue":"5","key":"2024080208112565000_ref16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2302892","article-title":"Health consequences of thymus removal in adults","volume":"389","author":"Kooshesh","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"2024080208112565000_ref17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12911-019-0780-5","article-title":"Natural language processing of radiology reports for identification of skeletal site-specific fractures","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"2024080208112565000_ref18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11121-012-0339-5","article-title":"An introduction to sensitivity analysis for unobserved confounding in nonexperimental prevention research","volume":"14","author":"Liu","year":"2013","journal-title":"Prev Sci"},{"issue":"1","key":"2024080208112565000_ref19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/biom.13558","article-title":"Sensitivity analyses informed by tests for bias in observational studies","volume":"79","author":"Rosenbaum","year":"2023","journal-title":"Biometrics"},{"issue":"5","key":"2024080208112565000_ref20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jbmr.3374","article-title":"Comorbidities only account for a small proportion of excess mortality after fracture: a record linkage study of individual fracture types","volume":"33","author":"Chen","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024080208112565000_ref21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/aje\/kwp425","article-title":"Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation","volume":"171","author":"Lee","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2024080208112565000_ref22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"2024080208112565000_ref23","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1359\/jbmr.090209","article-title":"Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture","volume":"24","author":"Eriksen","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024080208112565000_ref24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024080208112565000_ref25","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1159\/000520999","article-title":"Zoledronic acid contraindications prevalence among hip-fractured patients aged 75 years or over hospitalized in an orthogeriatric unit","volume":"68","author":"Jalbert","year":"2022","journal-title":"Gerontology"},{"issue":"18","key":"2024080208112565000_ref26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"2024080208112565000_ref27","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2106\/JBJS.K.01434","article-title":"Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures","volume":"94","author":"Gong","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"2024080208112565000_ref28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688269","article-title":"The effect of bisphosphonates on fracture healing time and changes in bone mass density: a meta-analysis","volume":"12","author":"Gao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2024080208112565000_ref29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.4453","article-title":"Bone mineral density and bone turnover 10 years after a single 5 mg dose or two 5-yearly lower doses of zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial","volume":"37","author":"Grey","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024080208112565000_ref30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024080208112565000_ref31","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","article-title":"Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis","volume":"179","author":"Cummings","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2024080208112565000_ref32","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"2024080208112565000_ref33","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2024080208112565000_ref34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024080208112565000_ref35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/clinem\/dgac636","article-title":"Comparisons between different anti-osteoporosis medications on postfracture mortality: a population-based study","volume":"108","author":"Wu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2024080208112565000_ref36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115566","article-title":"Bisphosphonates and lifespan","volume":"141","author":"Center","year":"2020","journal-title":"Bone"},{"issue":"1","key":"2024080208112565000_ref37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Colon-Emeric","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024080208112565000_ref38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198006","article-title":"Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: a prospective cohort study","volume":"13","author":"van Geel","year":"2018","journal-title":"PLoS One"},{"key":"2024080208112565000_ref39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2018.03.018","article-title":"Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis","volume":"111","author":"Wu","year":"2018","journal-title":"Bone"},{"issue":"1","key":"2024080208112565000_ref40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00223-021-00830-7","article-title":"Effect of zoledronate on lower respiratory infections in older women: secondary analysis of a randomized controlled trial","volume":"109","author":"Reid","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"2024080208112565000_ref41","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad161","article-title":"Response to letter to the editor from Riahi and Gruntmanis: \"Inpatient zoledronic acid and integrated orthopedic and fracture liaison services improve osteoporosis treatment rates\"","volume":"108","author":"Fan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024080208112565000_ref42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2202106","article-title":"Supplemental vitamin D and incident fractures in midlife and older adults","volume":"387","author":"LeBoff","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2024080208112565000_ref43","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00198-007-0403-3","article-title":"Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae101\/58713948\/zjae101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae101\/58713948\/zjae101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T04:32:33Z","timestamp":1722573153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article\/doi\/10.1093\/jbmr\/zjae101\/7702464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae101","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"article-number":"zjae101"}}